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Estradiol reverses renal injury in Alb/TGF-b1 transgenic mice.
Background. Men with chronic renal disease progress more
rapidly to renal failure than do women. Tranforming growth
factor-b (TGF-b) plays a central role in promoting progressive
renal injury, in part due to transcriptional effects mediated by
cooperation between Smad proteins and the transcription fac-
tor Sp1. Estrogen negatively regulates Sp1 activity and reverses
the stimulatory effects of TGF-b on type IV collagen synthesis
and cellular apoptosis in cultured mesangial cells. We hypothe-
sized that the ability of estradiol to reverse the effects of TGF-b
underlies gender dimorphism in the progression of chronic re-
nal disease.
Methods. We studied Alb/TGF-b transgenic mice, which
overexpress TGF-b1 and develop proteinuria and progressive
glomerulosclerosis. We implanted a sustained-release estradiol
pellet or a placebo pellet into control and Alb/TGF-b trans-
genic mice at 2 weeks of age. Animals were sacrificed at 5 weeks,
at which time urine, blood, and renal tissue were obtained for
study.
Results. The sustained-release estradiol pellet achieved a
physiologic concentration of estradiol. TGF-b levels were
higher in estradiol-treated mice compared to placebo-treated
mice. Proteinuria was reduced in estradiol-treated Alb/TGF-
b mice compared to placebo-treated transgenic mice. Mesan-
gial expansion and closure of capillary loops with enhanced
glomerular deposition of type I collagen, type IV collagen, and
tissue inhibitor of metalloproteinase (TIMP-2) was observed in
glomeruli of placebo-treated transgenic mice. Estrogen therapy
reversed these abnormalities.
Conclusion. Administration of estradiol to Alb/TGF-b trans-
genic mice, which overexpress TGF-b , ameliorated progressive
renal injury. The ability of estradiol to reverse the pro-fibrotic
effects of TGF-b , both in vitro and in vivo, may underlie the
sexual dimorphism in renal disease progression observed in
humans.
Men with chronic renal disease progress more rapidly
to end-stage renal failure than do women [1, 2]. Trans-
forming growth factor-b1 (TGF-b1) is centrally involved
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in mediating glomerulosclerosis and interstitial fibrosis
in chronic progressive renal injury. TGF-b1 acts, in part
through transcriptional effects mediated by cooperation
between Smad proteins and the transcription factor Sp1
[3–9]. We previously showed that activation of protein ki-
nase CK2 (CK2), a ubiquitous serine/threonine protein
kinase involved in signal transduction and transcriptional
regulation [10, 11], mediates TGF-b1–stimulated type
IV collagen gene transcription by increasing the quan-
tity of free Sp1 available to transactivate the collagen IV
promoter [12]. Since estrogen negatively regulates Sp1
transcriptional activity by inhibiting CK2 [13], we hypoth-
esized that estrogen might antagonize TGF-b1’s actions
via interactions involving CK2 and Sp1. We found that
estradiol reversed TGF-b1–stimulated type IV collagen
gene transcription by preventing TGF-b1–induced acti-
vation of CK2 [12]. We also demonstrated that TGF-b1
induces mesangial cell apoptosis via up-regulation of CK2
activity, which in turn phosphorylates p53 and initiates
an apoptotic cascade. Again, we showed that estradiol
reverses this process by preventing TGF-b1–induced ac-
tivation of CK2 [14].
We went on to postulate that CK2 mediates a broad
range of TGF-b’s actions that contribute to progressive
renal injury. We also hypothesized that antagonism be-
tween estradiol and TGF-b1, mediated by CK2/Sp1 inter-
actions, may contribute to the protective effect of female
gender on the progression of renal disease. In the present
report, we studied Alb/TGF-b mice, which overexpress
TGF-b1 and develop proteinuria and progressive renal
injury [15–17]. We used this model to test the hypothe-
sis that estradiol, by preventing CK2 activation, would
reverse the injurious effects of TGF-b1 and ameliorate
renal injury in this model.
METHODS
Animals
Four groups of mice were studied: (1) male Alb/TGF-b
transgenic mice (a gift of Snorri S. Thorgeirsson, M.D.,
Ph.D., NCI) treated with placebo (N = 9); (2) male
Alb/TGF-b mice treated with estradiol (N = 10); (3) wild-
type male C57BL/6JxCBA mice treated with placebo
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(Jackson Laboratories, Bar Harbor, ME, USA) (N =
5); and (4) wild-type male C57BL/6JxCBA mice treated
with estradiol (N = 5). A 17b-estradiol slow-release pel-
let (0.05 mg/pellet) (Innovative Research of America,
Sarasota, FL, USA) or a placebo pellet was implanted
in 2-week-old mice using a subcutaneous trochar (Inno-
vative Research of America). Blood and urine were col-
lected and kidney tissue harvested from mice sacrificed
at 5 weeks of age. A portion of each kidney was fixed by
immersion in buffered formalin and paraffin-embedded
for histologic examination, immunohistochemistry, and
detection of apoptosis.
Serum and urine creatinine concentrations were mea-
sured with a creatinine analyzer (Creatinine Analyzer 2;
Beckman Instrument, Fullerton, CA, USA). Total choles-
terol and triglyceride levels were measured in serum us-
ing colorimetric assays according to the instructions of
the manufacturer (Sigma Chemical Co., St. Louis, MO,
USA). Serum levels of TGF-b1 were measured by col-
orimetric enzyme-linked immunosorbent assay (ELISA)
(Quantikine) (R&D Systems, Minneapolis, MN, USA).
Serum estradiol and testosterone levels were measured
by radio immunoassay (Coat-a-Count; Diagnostic Prod-
ucts Corporation, Los Angeles, CA, USA). Estradiol lev-
els were measured at the time of sacrifice and in similarly
treated cohorts sacrificed at 3 and 4 weeks of age. Estra-
diol levels are presented as the average of the three mea-
surements. Urinary albumin concentration was measured
by enzyme-linked immunoassay [18].
For histopathology scoring, kidney tissue sections pre-
pared from each of the experimental groups were evalu-
ated in a blinded manner by a renal pathologist. Global
and segmental glomerulosclerosis, mesangial matrix ex-
pansion, mesangial cell hypercellularity, proximal tubule
cell hypertrophy, patency of capillary loops, and tubu-
lointerstitial injury were semiquantitatively assessed as
described in detail in previous publications from our labo-
ratory [19–21]. Mesangial deposition of types I and IV col-
lagen, tissue inhibitor of metalloproteinase-2 (TIMP-2),
matrix metalloproteinase-2 (MMP-2) and plasminogen
activator inhibitor-1 (PAI-1) was assessed by immunohis-
tochemistry and scored semiquantitatively as previously
described [22].
When data obtained from estradiol-treated C57BL/
6JxCBA mice and placebo-treated C57BL/6JxCBA mice
were identical, results from these two groups were com-
bined and the composite group referred to as the control
group.
Cellular apoptosis
In situ detection of DNA fragmentation in kidney tis-
sue sections from each of the experimental groups was as-
sessed utilizing the terminal deoxynucleotidyl transferase
(TdT)-mediated deoxyuridine triphosphate (dUTP) nick
end labeling (TUNEL) assay (ApoAlert DNA Fragmen-
tation Assay Kit) (Clontech Laboratories, Palo Alto, CA,
USA), by which fluorescein-dUTP incorporation at the
free ends of fragmented DNA can be visualized by fluo-
rescent microscopy. Cells were washed with phosphate-
buffered saline (PBS), fixed with 4% formaldehyde/PBS
for 30 minutes at 4◦C, permeabilized with 0.2% Triton
X-100/PBS for 15 minutes at 4◦C, and incubated with a
mixture of nucleotides and TdT enzyme for 60 minutes
at 37◦C in a dark, humidified chamber. The reaction was
terminated with 2× standard sodium citrate. The cells
were washed with PBS, and the coverslips were mounted
on glass slides with Crystal/mount (Biomeda, Foster City,
CA, USA). Fluorescent nuclei were detected by visualiza-
tion with a microscope equipped with fluorescein filters
(IX70) (Olympus America, Inc., Melville, NY, USA).
To confirm the TUNEL assay, apoptotic cells in tis-
sue sections were directly counted in a blinded fashion.
Morphologic criteria used to suggest apoptosis included
condensation of nuclear chromatin, convolution of the
nuclear membrane, fragmentation of nuclei, and shrink-
ing of cytoplasm.
Preparation of protein extracts from whole kidneys
Tissues were placed in chilled homogenizing buffer
[0.1 mol/L Tris, 0.1 mmol/L phenylmethylsulfonyl flu-
oride (PMSF), 5 mmol/L mercaptoethanol, and 0.01%
sodium azide, pH 7.2] (2 mL of buffer per gram of kidney
tissue). The tissue was homogenized on ice, and the resul-
tant homogenate was centrifuged at 6000 rpm for 4 min-
utes at 4◦C. The supernatant was collected and heated at
65◦C for 15 minutes, then stored at −70◦C.
Preparation of protein extracts from mesangial
cells grown in culture
Washed cellular monolayers were incubated for
20 minutes on a flat tray on a bed of crushed ice with 1 mL
of lysis buffer [50 mmol/L Tris-Cl, pH 8.0, 150 mmol/L
NaCl, 0.02% sodium azide, 0.1% sodium dodecyl sulfate
(SDS), 100 ng/mL PMSF, 1 lg/mL protinin, 1% Triton
X-100, and 0.5% sodium deoxycholate]. The resultant
lysate was scraped into a chilled microcentrifuge tube,
centrifuged at 1200g for 20 minutes, and the supernatant
stored at −70◦C.
Western blotting
Western blotting was performed on kidneys obtained
from each of the experimental groups and from total
cellular protein obtained from mesangial cells grown in
serum-free, phenol red-free RPMI supplemented with
the indicated agents for 24 hours. Protein content was
measured in a 0.1 mL aliquot of the concentrated media
(BioRad Protein Assay; BioRad, Hercules, CA, USA).
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To prepare the samples for SDS-polyacrylamide gel elec-
trophoresis (PAGE), 1 mL of 10% trichloroacetic acid
was added to 4 mg protein of concentrated media and
the final volume brought to 2 mL with distilled wa-
ter. The sample was vortexed and then centrifuged at
2000 rpm for 10 minutes. The pellet was dissolved in 1
mL of loading buffer (2% SDS, 10% glycerol, 50 mmol/L
Tris, 3% bromophenol blue, and 2% b-mercaptoethanol,
pH 7.6), boiled for 5 minutes, and then immediately
placed on ice. Twenty-five, 50, 75 or 100 lg of sample
were loaded for electrophoretic separation of proteins.
SDS-PAGE was performed using standard techniques
and proteins transferred to a polyvinylidene difluoride
(PVDF) microporous membrane. To correct for minor
differences in protein loading, blots were stained with
Amido Black (Sigma Chemical Co.) (Amido Black 10 g,
methanol 100 mL, glacial acetic acid 100 mL, and dis-
tilled water 800 mL), photographed for densitometry,
and then destained while rocking on a shaker for 15 to
20 minutes in destaining buffer (10% methanol and 10%
isopropranol).
Western blotting was performed using goat antibovine
type I collagen (Southern Biotechnology, Birmingham,
AL, USA), goat antibovine type IV collagen (South-
ern Biotechnology), rabbit antihuman PAI-1 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), goat antihuman
TIMP-2 (Santa Cruz Biotechnology), and goat antihu-
man MMP-2 (Santa Cruz Biotechnology). After blot-
ting, the membrane was immediately placed into blocking
buffer [2% bovine serum albumin (BSA)in wash buffer
consisting of 10 mmol/L Tris, 100 mmol/L NaCl, 0.1%
Tween 20] on a shaking apparatus for 30 minutes at 37◦C.
The membrane was next washed for 30 minutes with ag-
itation. After washing, the membrane was treated with
Enhanced Chemiluminescence Reagent (Amersham
Life Science, Arlington Heights, IL, USA) according to
the manufacturer’s instructions. Kodak X-OMAT 4R film
(Eastman Kodak, Rochester, NY, USA) was exposed to
the blot for 10 minutes. Negative controls using irrele-
vant antibodies and positive controls were performed as
indicated.
Protein kinase CK2 enzyme activity
Protein kinase CK activity was measured in total cellu-
lar extracts according to the method of Heller-Harrison
and Czech [23]. Cells were washed with ice-cold PBS and
scraped using a rubber policeman into a buffer solution
containing 80 mmol/L b-glycerophosphate, 20 mmol/L
ethyleneglycol tetraacetate (EGTA), 15 mmol/L MgCl2,
50 mmol/L NaF, 100 mmol/L NaVO4, 0.1 mmol/L PMSF,
and 10 lg/mL aprotinin, pH 7.3. The solution was lysed by
drawing through a 22 gauge needle 20 times and then cen-
trifuged at 22,000 × g for 20 minutes. Thirty micrograms
of protein was assayed at 30◦C in 20 lL of assay buffer
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Fig. 1. Effect of transforming growth factor-b1 (TGF-b1), estradiol,
and the specific protein kinase CK2 inhibitor, 5,6 dichloro-1-b-D-
ribofuranosylbenzimidazole (DRB), on the synthesis of type I colla-
gen, plasminogen activator inhibitor-1 (PAI-1) and tissue inhibitor of
metalloproteinase-2 (TIMP-2) by cultured murine mesangial cells. Ab-
breviations are: C, control; T, TGF-b1; E, estradiol.
containing 100 mmol/L Tris-HCl, pH 8.0, 100 mmol/L
NaCl, 50 mmol/L KCl, 20 mmol/L MgCl2, 100 lmol/L
NaVO4, 1 mmol/L RRREEETEEE (a specific substrate
for CK2 [24]) (Alexis Biochemicals, San Diego, CA,
USA), and 20 lmol/L [c−32P] adenosine triphosphate
(ATP) (Amersham Pharmacia BioTech, Piscataway, NJ,
USA). Reactions were terminated after 10 minutes by the
addition of 0.01 mol/L ATP and 0.4 N HCl. After trichlo-
racetic acid precipitation, the precipitates were incubated
on ice for 5 minutes and 12.5 lL was spotted onto 1.5 cm2
pieces of Whatman p81 paper. The paper was washed
with 0.5% H2PO4 and counted in a liquid scintillation
counter. Counts obtained in control reactions run with-
out cells were subtracted as background.
Statistics
Data are expressed as means ± SEM. Differences
among groups were tested by analysis of variance with
Scheffe’s correction. P < 0.05 was considered a signifi-
cant difference.
RESULTS
In vitro studies
Exposure to TGF-b1 (2 ng/mL, 24 hours) increased
type I collagen, PAI-1, and TIMP-2 protein levels in
cultured murine mesangial cells (321 ± 23, 198 ± 17, and
240 ± 31, expressed as a percent of values obtained in
control untreated cells, P < 0.001 vs. control) (Fig. 1). Co-
incubation with a physiologic concentration of estradiol
(10−9 mol/L) completely reversed the effects of TGF-b1
on these proteins (104 ± 8, 95 ± 7, and 109 ± 11, P not
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Table 1. Renal histopathology and immunohistochemistry in placebo-treated Alb/transforming growth factor-b (TGF-b), estradiol-treated
Alb/TGF-b , placebo-treated C57BL/6JxCBA, and estradiol-treated C57BL/6JxCBA mice
Placebo-treated Estradiol-treated Placebo-treated Estradiol-treated
Alb/TGF-b Alb/TGF-b C57BL/6JxCBA C57BL/6JxCBA
Renal histopathology
Mesangial expansion 2.2 ± 0.2 0.4 ± 0.1a Absent Absent
Capillary loop closure 2.1 ± 0.3 0.8 ± 0.2a Absent Absent
Proximal tubule cell hypertrophy 1.3 ± 0.2 0.7 ± 0.1b Absent Absent
Mesangial hypercellularity 1.6 ± 0.2 1.2 ± 0.2 Absent Absent
Tubular vacuolization 0.8 ± 0.1 0.8 ± 0.2 Absent Absent
Tubulointerstitial cellular infiltration 0.3 ± 0.1 0.2 ± 0.1 Absent Absent
Immunohistochemistry
Type I collagen 2.4 ± 0.2 0.3 ± 0.1a 0.2 ± 0.1 0.2 ± 0.1
Type IV collagen 2.8 ± 0.3 0.3 ± 0.1a 0.2 ± 0.1 0.3 ± 0.1
TIMP-2 2.1 ± 0.2 0.4 ± 0.2a 0.2 ± 0.1 0.1 ± 0.1
PAI-1 1.8 ± 0.3 1.7 ± 0.2 0.3 ± 0.1 0.2 ± 0.1
MMP-2 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.3 ± 0.1
Abbreviations are: TIMP-2, tissue inhibitor metalloproteinase-2; PAI-1, plasminogen activator inhibitor-1; MMP-2, matrix metalloproteinase-2.
aP < 0.01 vs. placebo-treated Alb/TGF-b mice.
bP < 0.05 vs. placebo-treated Alb/TGF-b mice.
2-week-old
control
5-week-old
control
5-week-old
Alb/TGF-β
5-week-old
Alb/TGF-β
+ estradiol
Fig. 2. Periodic acid-Schiff staining of kid-
ney sections from 2-week-old control, 5-
week-old placebo-treated control, 5-week
old placebo-treated Alb/transforming growth
factor-b (TGF-b) and 5-week-old estradiol-
treated Alb/TGF-b mice.
significant vs. control) (Fig. 1). Similarly, coincubation
with 5,6 dichloro-1-b-D-ribofuranosylbenzimidazole
(DRB) (10−6 mol/L), a selective inhibitor of CK2 activity
[11, 25], reversed TGF-b1’s actions (112 ± 8, 104 ± 6,
and 97 ± 10, pNS vs. control). Neither estradiol alone
nor DRB alone had any effect on type I collagen, PAI-1,
or TIMP-2 protein levels.
In vivo and ex vivo studies
Body weight did not differ among the groups at the time
of sacrifice. TGF-b1 levels were significantly higher in 5-
week-old estradiol-treated Alb/TGF-b mice compared
to placebo-treated Alb/TGF-b mice (3134 ± 180 pg/mL
vs. 2322 ± 215 pg/mL) (P < 0.02). There was no sig-
nificant difference in time-averaged estradiol levels be-
tween estradiol-treated Alb/TGF-b and estradiol-treated
C57BL/6JxCBA mice. Time-averaged estradiol levels
were significantly higher in estradiol-treated Alb/TGF-
b and estradiol-treated C57BL/6JxCBA mice compared
to placebo-treated Alb/TGF-b mice (186.8 ± 50.4 pg/mL
vs. 14.7 ± 3.6 pg/mL) (P < 0.001) or placebo-treated
C57BL/6JxCBA mice (20.2 ± 3.0 pg/mL) (P < 0.01).
At the time of sacrifice, serum testosterone levels
did not differ between estradiol-treated Alb/TGF-b
and C57BL/6JxCBA mice compared to placebo-treated
Alb/TGF-b and C57BL/6JxCBA mice (13.5 ± 2.3 pg/mL
vs. 18.3 ± 1.9 pg/mL) (P = 0.15).
There was no significant difference among the
groups in serum levels of creatinine, total choles-
terol or triglycerides. The urinary albumin to creati-
nine ratio was greater in placebo-treated Alb/TGF-b
mice compared to estradiol-treated Alb/TGF-b mice,
estradiol-treated C57BL/6JxCBA mice or placebo-
treated C57BL/6JxCBA mice (27.4 ± 6.4 vs. 14.0 ± 3.1
vs. 2.0 ± 0.2 vs. 2.6 ± 0.3) (P < 0.05). Semiquantitative
assessment of renal histology showed that renal damage
was markedly ameliorated in estrogen-treated compared
to placebo-treated Alb/TGF-b mice (Table 1) (Fig. 2).
Scoring was significantly higher in placebo-treated versus
estrogen-treated transgenic mice for the following fea-
tures: mesangial expansion, capillary loop closure, and
proximal tubule cell hypertrophy (Table 1). No signifi-
cant differences were observed in mesangial cellularity,
tubular vacuolization or tubulointerstitial cell infiltration
(Table 1). No renal pathology was detected in 2- or
5-week-old placebo-treated C57BL/6JxCBA mice or
in 5-week-old estradiol-treated C57BL/6JxCBA mice
(Table 1) (Fig. 2).
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Fig. 3. Measurement of type I collagen by Western blotting in kid-
neys obtained from control, placebo-treated Alb/transforming growth
factor-b (TGF-b), and estradiol-treated Alb/TGF-b mice.
Measurement of type I collagen by Western blotting
in whole kidney specimens obtained at the time of sac-
rifice showed an increase in placebo-treated Alb/TGF-b
mice that was completely reversed by estradiol treatment
(257 ± 21 vs. 107 ± 8) (P < 0.001, expressed as a percent
of control values) (Fig. 3).
Immunohistochemistry was performed to assess stain-
ing for type I collagen, type IV collagen, PAI-1, TIMP-2,
and MMP-2 (Table 1). Heavy staining for type I and type
IV collagen, PAI-1, and TIMP-2 was observed within the
glomerular mesangium of all placebo-treated Alb/TGF-
b mice. In contrast, staining for type I and type IV col-
lagen and for TIMP-2 was modest in estrogen-treated
Alb/TGF-b mice and in estradiol-treated and placebo-
treated C57BL/6JxCBA mice. We were unable to demon-
strate a reduction in mesangial staining for PAI-1 or an
increase in MMP-2 staining attributable to estradiol ther-
apy in transgenic mice.
Apoptosis of tubular and glomerular cells was fre-
quently observed by TUNEL assay in kidney sections
obtained from placebo-treated Alb/TGF-b mice but was
significantly reduced by estradiol treatment (12 ± 2 vs.
3 ± 1 cells/high power field) (P < 0.01) (Fig. 4). Direct
counting of apoptotic cells in tissue sections confirmed
the greater number of apoptotic cells in placebo-
treated Alb/TGF-b mice compared to estradiol-treated
Alb/TGF-b mice (8 ± 2 vs. 2 ± 1) (P < 0.001). Apop-
totic cells were only rarely observed in control (estradiol-
treated and placebo-treated C57BL/6JxCBA) mice.
CK2 activity was measured in whole kidney extracts
obtained at the time of sacrifice. CK2 activity was
greater in placebo-treated Alb/TGF-b mice compared to
estradiol-treated Alb/TGF-b mice (3277 ± 103 vs. 2638 ±
Alb/TGF-β Alb/TGF-β
+ estradiol
Fig. 4. Apoptosis assessed by terminal deoxynucleotidyl transferase
(TdT)-mediated deoxyuridine triphosphate (dUTP) nick end la-
beling (TUNEL) assay in placebo-treated and estradiol-treated
Alb/transforming growth factor-b (TGF-b) mice. Arrows indicated
apoptotic nuclei.
215) (P < 0.02) or control (estradiol-treated and placebo-
treated C57BL/6JxCBA) mice (2473 ± 247) (P < 0.02).
DISCUSSION
We have previously shown that gender exerts a major
impact on the rate of progression of chronic renal dis-
ease [1, 2]. In a meta-analysis that examined the effect
of gender on the rate of deterioration of renal function
in non-diabetic renal disease using 68 studies containing
11,345 patients, we found that men with chronic renal fail-
ure show a more rapid decline in renal function with time
than do women [26].
Since TGF-b1 is the major mediator of glomeruloscle-
rosis and interstitial fibrosis in progressive renal injury,
we hypothesized that interactions between estradiol and
TGF-b1 may contribute to the renoprotective effect of fe-
male gender [12]. We showed that the transcription factor
Sp1 mediates the stimulatory effect of TGF-b1 on type
IV collagen gene transcription and protein synthesis [27]
and that estradiol, in physiologic concentrations, reverses
TGF-b1–stimulated type IV collagen synthesis by inter-
fering with TGF-b1/Sp1 interactions [12]. We found that
antagonism between estradiol and TGF-b1 was mediated
by protein kinase CK2, a ubiquitous serine/threonine pro-
tein kinase which plays an important role in signal trans-
duction, transcriptional regulation, and cell division [10,
11]. We explained this antagonism by demonstrating that
TGF-b1 and estradiol signaling pathways interact at the
level of CK2 to regulate the amount of free Sp1 available
to transactivate the type IV collagen promoter [12]. We
also showed that CK2 mediates the ability of TGF-b1
to induce mesangial cell apoptosis and that physiologic
concentrations of estradiol reverse TGF-b1–stimulated
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mesangial cell apoptosis by reversing activation of CK2
[14].
Since many of the actions of TGF-b1 are transduced
by Sp1 in cooperation with Smad proteins [3–9, 27–32],
modulation of Sp1 transcriptional activity by CK2 may
mediate a broad range of TGF-b1’s actions and may be
subject to antagonism by estradiol. To test this hypothesis,
we examined whether estradiol and DRB, a potent and
specific inhibitor of CK2 activity, would reverse cellular
actions of TGF-b1. We studied the expression of proteins
involved in progressive renal injury that are transacti-
vated by Sp1-dependent promoters. In the present study,
we found that both DRB and estradiol reversed TGF-b1–
stimulated synthesis of type I collagen, PAI-1 and TIMP-2
in murine mesangial cell cultures.
Mice that are transgenic for the murine albumin en-
hancer/promoter linked to a full length porcine TGF-b1
gene on the Y chromosome (Alb/TGF-b mice) develop
chronic progressive renal injury leading to widespread
glomerulosclerosis [15–17]. These mice express the trans-
gene exclusively in the liver and show elevated circulat-
ing levels of TGF-b1 as early as 2 weeks of age [15–17].
Glomerular injury develops in 100% of mice and is first
detected by light microscopy at 2 to 3 weeks of age and
becomes severe at 5 weeks of age [15]. We utilized this
animal model to study the effects of TGF-b1 overexpres-
sion on renal CK2 enzyme activity and to study the effects
of estradiol on the development of renal injury.
We found that estradiol reverses TGF-b1–mediated re-
nal injury in Alb/TGF-b transgenic mice as reflected by
reductions in proteinuria, mesangial expansion, capillary
loop closure, proximal tubule cell hypertrophy, glomeru-
lar deposition of types I and VI collagen, glomeru-
lar TIMP-2 staining, and cellular apoptosis. We also
found that CK2 activity was increased in placebo-treated
Alb/TGF-b1 mice compared to control mice and that
estradiol treatment normalized this enhanced activity in
transgenic mice.
In cultured mesangial cells, the ability of estradiol to
prevent TGF-b1–induced up-regulation of CK2 activity
translates into reversal of TGF-b1–stimulated synthesis
of proteins involved in promoting fibrosis and progressive
renal injury. In mice over-expressing TGF-b1, the ability
of estradiol to prevent TGF-b1–induced up-regulation of
CK2 activity translates into reversal of renal injury. Our in
vitro data provide a rationale for our in vivo observations
and suggest a central role for CK2 both in mediating the
deleterious actions of TGF-b on the kidney and in the
reversal of these actions by estradiol. These interactions
may explain the protective effects of female gender on
the course of chronic renal disease.
The Alb/TGF-b mice we utilized descended from line
25 described by Kopp et al [16]. Serum TGF-b levels
are markedly elevated at 3 weeks of age but decline by
6 weeks of age to levels not significantly different from
those of control mice [16]. The ability of estradiol to ame-
liorate progressive renal injury in TGF-b mice was not
mediated by a reduction in serum levels of TGF-b1. In
fact, estradiol raised serum TGF-b1 levels in these mice,
suggesting that antagonism of TGF-b1’s actions accounts
for estradiol’s renoprotective effects.
We studied Alb/TGF-b1 and control mice between the
ages of 2 and 5 weeks, prior to the onset of puberty. An-
drogen levels in C57BL mice are low until 35 days of
age at which time they gradually increase. The puber-
tal increase in androgen levels does not attain statistical
significance until 70 days of age [33] and does not peak
until 6 months of age [34]. Moreover, we observed no
difference in serum testosterone levels among estradiol-
treated Alb/TGF-b1 mice, placebo-treated Alb/TGF-b1
mice, and control mice. Since testosterone levels were
low and were not altered by estradiol treatment, we do
not think that the presence of androgens influenced our
results.
Nephrogenesis in mice continues until approximately
2 weeks of age. Since TGF-b1 levels are elevated and
glomerular lesions can be detected in 2- to 3-week-old
Alb/TGF-b1 mice, it is possible that TGF-b1–induced
developmental abnormalities contribute to the genesis
of renal disease in this model. However, the beneficial ef-
fects of estradiol cannot be attributed to reversal of TGF-
b1–induced developmental abnormalities since estradiol
treatment was not initiated until 2 weeks, at which time
nephrogenesis was complete. Given that this model uses
immature mice, extrapolation of the results to adult forms
of disease may be limited.
Renal injury was not associated with hypertriglyc-
eridemia in 5-week-old Alb/TGF-b mice. This
distinguishes our model from those in which severe
hypertriglyceridemia accompanies renal injury [35, 36].
In these models, estrogen therapy accelerates renal
injury, presumably via estrogen-induced exacerba-
tion of hypertriglyceridemia [35, 36]. Since estrogen
causes only a modest increase in triglyceride levels in
postmenopausal women [37–39], our model of estradiol-
treated Alb/TGF-b mice may better reflect the human
condition than do models of renal injury in which
estrogen induces severe hypertriglyceridemia. However,
we are not aware of any studies in which the effect of
estradiol on triglyceride levels in nephrotic women was
assessed.
CONCLUSION
We have shown that estradiol antagonizes the effects
of TGF-b both in vitro, in cultured mesangial cells, and in
vivo, in a model of progressive renal injury mediated by
overexpression of TGF-b1. This antagonism may explain
sexual dimorphism in renal disease progression.
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